Aducanumab and UsAgainstAlzheimer’s

Aducanumab is a proposed treatment for early Alzheimer’s disease that is intended to slow the progression of the disease. UsAgainstAlzheimer’s (UsA2) urged the U.S. Food and Drug Administration to approve aducanumab.

Share:

Sign Up for More Information

"Biogen, Medicare, private insurers, and the FDA must immediately address patient concerns about affordability, equity, effectiveness, and whether [Aduhelm] is right for them. UsAgainstAlzheimer’s stands ready to help."

Read UsAgainstAlzheimer's full statement - New Alzheimer’s Treatment Must Be Affordable and Accessible; with Faster and More Inclusive Phase 4 Confirmatory Trial

"We urge the FDA to approve aducanumab and put in place a platform to assess the real-world experience with the drug by persons in the early stages of Alzheimer’s disease." (Read the full letter UsA2 sent to the FDA.)

George Vradenburg and Russ Paulsen

Co-Founder and Chairman, UsAgainstAlzheimer's and Chief Operating Officer, UsAgainstAlzheimer's.

“Alzheimer’s is a disease of greater prevalence and greater lethality than Covid-19. This is an ongoing pandemic. Its cost to America in terms of direct medical costs is significantly higher than cancer.” (Read the full article in Barron's.)

George Vradenburg

Co-Founder and Chairman, UsAgainstAlzheimer's

About Aducanumab

  • Aducanumab is a proposed treatment for early Alzheimer’s disease that is intended to slow the progression of the disease. Aducanumab does this by promoting clearance of amyloid beta plaques, a hallmark of Alzheimer’s, from the brain. It has the potential to slow the rate of cognitive and functional decline in persons in the earlier stages of Alzheimer’s and may help preserve the cognitive abilities and functions of these patients for a longer time.

  • Aducanumab, which has been developed by Biogen, is currently being reviewed by the Food and Drug Administration, with a decision expected by the first quarter of 2021.

  • If approved, aducanumab would be the first disease-modifying therapy approved for use in the U.S.

  • Aducanumab was studied in people living with early-stage Alzheimer’s disease; it has not been studied in individuals with moderate to severe Alzheimer’s.

Aducanumab and UsAgainstAlzheimer’s

UsAgainstAlzheimer’s (UsA2) has urged the U.S. Food and Drug Administration to approve aducanumab. By delaying the progression for people in the early stages of the disease, this drug therapy will give people more time to live independently and perform daily activities longer.

To people living with the disease and their caregivers, every single day matters. Approval of this drug also would be a powerful sign of hope for people living with Alzheimer’s after years of disappointment.

UsA2 also believes that FDA approval of aducanumab would have a ripple effect on pharmaceutical innovation that could spark additional investment by other companies in disease-modifying treatments and therapies.

Statements by UsAgainstAlzheimer’s to FDA Advisory Committee:

Resources

  • Resources

    Changing Face of Alzheimer's: A Survey on Burden for Caregivers from Communities of Color

  • Resources

    Changing Face of Alzheimer's: A Survey on Relationships of Caregivers of Color with Health Care Providers

  • Resources

    CDC Healthy Aging Letter - May 2018, 2021

  • Resources

    COVID19 and Brain Health: Advancing Equity for Caregivers & Communities

  • Resources

    UsAgainstAlzheimer's Letter to FDA on Pimavanserin (5.3.21)

  • Resources

    Paid Family and Medical Leave Joint Letter (NAC, UsAgainstAlzheimer's, The Arc)

In the News